4D Molecular Therapeutics

FDMTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$561.970 M

$10.75 +1.90%

Close of 7 Aug 2026

Revenue

$85.2M

#2573 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

52,271,648

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#60Tectonic TherapeuticTECX$584.6M
#61Zura BioZURA$566.7M
#624D Molecular TherapeuticsFDMT$562.0M
#63Autolus TherapeuticsAUTL$561.6M
#64Prime MedicinePRME$556.3M

Where these numbers come from

Share counts and financials for 4D Molecular Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.